

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3974558
<b>Application Number:</b>	10657363
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3135
<b>Title of Invention:</b>	Ultra high affinity neutralizing antibodies
<b>First Named Inventor/Applicant Name:</b>	James F. Young
<b>Customer Number:</b>	20583
<b>Filer:</b>	Tamera Weisser/Eric Baclog
<b>Filer Authorized By:</b>	Tamera Weisser
<b>Attorney Docket Number:</b>	10271-159-999
<b>Receipt Date:</b>	22-SEP-2008
<b>Filing Date:</b>	08-SEP-2003
<b>Time Stamp:</b>	20:04:28
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	LAMPRECHT_I_Infect_Dis_211.pdf	508051 <small>5a62ec52807546e8721246eb1ef791fec853579</small>	no	7

**Warnings:**

**Information:**

2	NPL Documents	LANDRY_Infec_Dis_166A_969.pdf	238876 55b41923913a623110b31d1d15012a05bc090666	no	2
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	LOBUGLIO_PNAS_4220.pdf	511367 8f5a18ec43f90d8fa9a71ac79bd0f5927ce14	no	5
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	MACDONALD_N_Eng_J_Med_397.pdf	559029 ce0cf1740c200066516ef1c11e7d464dab0c80a0	no	4
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	MALLEY_J_Infect_Dis_1555.pdf	559932 cc4157730feb075a4b103c45ced0502c4094e0b	no	7
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	MARKS_Biotechnology_779.pdf	607390 cd37381325db22b40419b8ba029137819240c18	no	5
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	MCARTHUR-VAUGHAN_J_Med_Primateol_61.pdf	1180079 aa02048c369974864863accef95a23ab04623	no	14
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	MEDIMMUNE_BioSpace_Beat_Nov_6_2006.pdf	478035 f77c113d8cb855aaf18cb354475239376103c0b	no	4
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	MEDIMMUNE_BioSpace_Beat_Sept_1_2005.pdf	458829 d4b148b6abf7005d6290116c0f0cd6522678a0	no	3
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	MEDIMMUNE_Synagis_Packag_e_Insert_1999.pdf	202018 d4ba89227aef1e4f05a5c1536de12358e958b1	no	1
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	MEDIMMUNE- INC_Synagis_Package_Insert_2 002.pdf	265380 e502a0126bc3d818b5d2259299321b5 b55d9f9	no	1
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	MEISSNER_Antimicrob_Agents _Chemother_1183.pdf	621945 d094db14c5105743584db4f5e53d27c47f e1508a	no	6
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Motavizumab_vs_Palivizumab_ Inpharma_5.pdf	132849 2d40f91a5212302611186f1b3c3b324b184c a080f	no	1
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	MURPHY_J_Virol_3907.pdf	396728 d6a11a0c30c06d7c1f75726c2ad4d5a30c 6a76b	no	4
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	MURPHEY_Vaccine_185.pdf	374740 2c991491c6da1f0b1e01ee630017357869de5 b586c	no	5
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	NAVAS_J_Pediatr_348.pdf	547037 3c9d88ddc77dcb78623556df7c3c2abe9dcf adac	no	7
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	NGUYEN_Clin_Exp_Immunol_8 5.pdf	1203872 7b1e0f2d7dbda0a11395466234dc56578d d5c0	no	9
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	PALOMO_J_Virol_4199.pdf	1130966 517d92a212984ab06dc9c20093800478bc7 788f	no	8
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Phys_Des_Ref_55th_Ed_1863. pdf	601114 9d1d80c9a1e98c3634c0b6f6a17ba73d92f 551e	no	3
<b>Warnings:</b>					
<b>Information:</b>					

20	NPL Documents	PRINCE_Infect_Immun_81.pdf	471373 <small>3daDec1666478322208e6f553511e09f1812597</small>	no	7
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			11049610		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					